Femasys Inc(NASDAQ:FEMY) is a biomedical company focused on women's healthcare.

The company, with a market capitalization of $22.50 million as of data from Benzinga Pro on 17 June, went public in June 2021.

In an emailed interview withBenzinga,Kathy Lee-Sepsick, the founder & CEO of Femasys, said, "I considered permanent birth control but found the available options too risky."

Femasys' commercially available products are:

• FemaSeed:A form of artificial insemination where sperm is delivered directly and safely into the fallopian tube
• FemVue:A contrast-generating device for ultrasound evaluation.
• FemCath: A delivery catheter for fallopian tube and uterine cavity...